Nothing new. He makes a reasonable case for why Marquibo should be approvable - good efficacy and safety in 2nd relapse population and a history by the FDA of similar approvals (i.e. small single-agent studies in difficult-to-treat settings). But regardless of whether you believe the story, the company doesn't have the cash to get them to approval, which would be mid-next year. And since he offers hints of other funding mechanism (e.g. partnering Medadione or one of the other drugs), the only conclusion you are left with is a ultra-dilutive offering, so why would you buy it now. For those of us already long, you can only hope that they sell the company or partner something.